Adc Therapeutics SA (ADCT) Peer Comparison

$1.12

$0.07 (6.67%)

As on 21-Sep-2026 16:26EDT

Market cap

$135 Mln

Revenue (TTM)

$79 Mln

P/E Ratio

--

P/B Ratio

3.4

Div. Yield

0 %

Edit

	Adc Therapeutics SA (ADCT)	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR
Market cap ($ Mln)	135	5,469	261
Revenue ($ Mln)	79	13	18
Net Profit ($ Mln)	-96.91	-451.14	-43.16
Net Margin (%)	-123.03	-3,368.72	-246.49
RoE (%)	--	-24.60	-107.75
Price to Earnings	--	--	--
Price-To-Book	3.42	3.17	6.21

Cashflow
Ratios

Cashflow ($ Mln)

	Adc Therapeutics SA (ADCT)	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR
Cash From Operating Activities	-141.17	-345.01	-66.15
Cash Flow from Investing Activities	0.40	-31.81	60.69
Cash from Financing Activities	150.95	426.03	-0.97
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Adc Therapeutics SA (ADCT)	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR
ROCE (%)	-164.38	-26.01	-84.28
ROE (%)	73.43	-24.60	-107.75
ROA (%)	-25.78	-18.35	-15.99
EBIT Margin (%)	-53.31	-3,529.79	-172.39
Net Margin (%)	-123.03	-3,368.72	-246.49
Cash Profit Margin (%)	0.00	0.00	0.00

Growth Ratios

	Adc Therapeutics SA (ADCT)	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR
Revenue Growth (%)	1.97	-64.15	-39.45
EBIT Growth (%)	64.72	-1.92	40.04
Net Profit Growth (%)	42.98	3.56	14.56
EPS Growth (%)	57.71	10.70	13.75
Book Value Growth (%)	15.93	-7.92	-52.01

Valuation Ratios

	Adc Therapeutics SA (ADCT)	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR
Price / Earnings	-3.72	-8.11	-4.51
Price / Book Value	-2.86	2.45	7.07
Dividend Yield (%)	--	--	--
EV/EBITDA	-7.93	-5.60	-3.40
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Adc Therapeutics SA (ADCT)	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR
Debt to Equity	-0.48	0.34	0.00
Short term debt to equity ratio	-0.03	0.01	0.02
Current Ratio	3.03	17.85	0.93
Quick Ratio	2.97	17.85	0.93
Interest Coverage	-0.86	--	-200.97

Operating Efficiency Ratios

	Adc Therapeutics SA (ADCT)	Crispr Therapeutics AG (CRSP)	AC Immune SA - ADR
Debtors to sales (%)	35.59	0.00	77.93
Asset Turnover	0.21	0.01	0.06
Receivable days	110.96	1,300.75	124.56
Inventory Days	537.14	--	--
Payable days	647.40	20.26	--
Cash Conversion Cycle	0.71	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly